Table 1_Evolocumab early reduces IL-1β/IL-17A and improves left ventricular function in ST

257 STEMI patients were divided into two groups and observed for 12 weeks to study the effects of the PCSK9 inhibitor evolocumab on inflammatory factors and left ventricular function. The dataset contains results from a real-world observational study, including percentage changes in interleukin levels and left ventricular ejection fraction. The data was authored by Menglong Zhang and last updated on May 8, 2026.

Use Cases

• Analyzing the relationship between PCSK9 inhibitor use and reductions in inflammatory markers like IL-1β and IL-17A.
• Modeling predictors of left ventricular function improvement (ΔEF≥5%) in STEMI patients.
• Conducting mediation analysis to quantify the proportion of cardiac improvement attributable to specific cytokine reductions.
• Comparing treatment outcomes between statin-only and statin-plus-evolocumab therapy over a 12-week period.

Strengths

• Dataset is based on a study of 257 STEMI patients, providing a defined cohort size.
• Results include specific percentage changes with statistical significance values (e.g., -29.35% vs -25.27%, P = 0.012).
• Clear temporal structure with measurements at 4 weeks and 12 weeks post-treatment.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 50.5 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Real-world observational study dividing patients based on prescriptions.

Time Range

Observation period of 12 weeks per patient.

Freshness

Last updated 2026-05-08 05:54:48; freshness should be verified.

Geography

null